Trials / Conditions / Bispecific Antibody
Bispecific Antibody
5 registered clinical trials studyying Bispecific Antibody — 4 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymp NCT07231250 | Li Zhiming | Phase 2 |
| Recruiting | Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcome NCT07309497 | University of Zurich | — |
| Not Yet Recruiting | A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC NCT07086326 | Yang Fan, MD | Phase 2 |
| Not Yet Recruiting | Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable No NCT06946836 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Completed | A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. NCT05228470 | Pfizer | Phase 2 |